文献速递核素与放射性配体治疗肿瘤 PET/CT

肝移植前接受放射性肝段切除术的肝细胞癌实现完全病理坏死:玻璃微球综合分析

Achieving Complete Pathologic Necrosis in Hepatocellular Carcinoma Treated with Radiation Segmentectomy before Liver Transplantation: A Comprehensive Glass Microsphere Analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-11

该研究为已发表队列的二次分析,纳入61个肝移植前接受钇-90玻璃微球放射性肝段切除术的早期肝细胞癌肿瘤,采用治疗后轫致辐射SPECT-CT进行单室、多室及基于体素的剂量学分析,比较完全病理坏死组与非完全病理坏死组。结果显示特定比活度、总血管体剂量、肿瘤剂量及血管体肝实质剂量阈值可预测完全病理坏死。

要点

  • 比活度≥570 Bq、总血管体剂量≥439 Gy、肿瘤剂量≥844 Gy、血管体肝实质剂量≥420 Gy可预测完全病理坏死。
  • 比活度<570 Bq亚组中,总血管体剂量≥263 Gy、肿瘤剂量≥451 Gy及平均血管体粒子密度≥11.4×10³/ml可预测完全病理坏死。
  • 满足所有治疗参数阈值的肿瘤中88%实现完全病理坏死,而未满足任一标准者为零。

核心结论

  • 完全病理坏死可由比活度≥570 Bq、总血管体剂量≥439 Gy、肿瘤剂量≥844 Gy和血管体肝实质剂量≥420 Gy预测。
  • 在比活度<570 Bq的肿瘤中,总血管体粒子密度≥11.4×10³/ml与完全病理坏死相关。
  • 按所确定阈值优化后,单室与多室剂量学表现相似。

研究设计与样本

  • 本研究为对既往发表队列的二次分析,纳入61个肝移植前接受钇-90玻璃微球放射性肝段切除术且有治疗后影像的肿瘤。
  • 采用剂量确认软件进行治疗后轫致辐射SPECT-CT单室、多室及基于体素的剂量学分析,比较完全病理坏死组与非完全病理坏死组。

主要发现

  • 完全病理坏死组(n=43)与非完全病理坏死组(n=18)相比,中位比活度为1242 vs 867 Bq(p=0.018),总血管体剂量为577 vs 352 Gy(p=0.005),肿瘤剂量为1086 vs 738 Gy(p=0.007),血管体肝实质剂量为490 vs 309 Gy(p=0.005)。
  • ROC曲线分析显示,比活度≥570 Bq(AUC 0.69,敏感度88%,特异度50%)、总血管体剂量≥439 Gy(AUC 0.73,敏感度70%,特异度67%)、肿瘤剂量≥844 Gy(AUC 0.72,敏感度76%,特异度67%)、血管体肝实质剂量≥420 Gy(AUC 0.73,敏感度60%,特异度78%)可预测完全病理坏死(p<0.05)。
  • 完全病理坏死组与非完全病理坏死组的肿瘤或血管体粒子密度、肿瘤体积及血管体体积无统计学差异。
  • 比活度<570 Bq亚组(n=15)的ROC分析显示,总血管体剂量≥263 Gy(AUC 0.85,敏感度83%,特异度89%)、肿瘤剂量≥451 Gy(AUC 0.83,敏感度100%,特异度67%)及平均血管体粒子密度≥11.4×10³/ml(AUC 0.81,敏感度83%,特异度79%)可预测完全病理坏死(p<0.05)。
  • 满足所有已确定治疗参数阈值的肿瘤中88%实现完全病理坏死,而未满足任一标准者为零。

关键数值与推荐

  • 比活度≥570 Bq(AUC 0.69,敏感度88%,特异度50%)预测完全病理坏死(p<0.05)。
  • 总血管体剂量≥439 Gy(AUC 0.73,敏感度70%,特异度67%)预测完全病理坏死(p<0.05)。
  • 肿瘤剂量≥844 Gy(AUC 0.72,敏感度76%,特异度67%)预测完全病理坏死(p<0.05)。
  • 血管体肝实质剂量≥420 Gy(AUC 0.73,敏感度60%,特异度78%)预测完全病理坏死(p<0.05)。
  • 比活度<570 Bq亚组中,总血管体剂量≥263 Gy(AUC 0.85,敏感度83%,特异度89%)、肿瘤剂量≥451 Gy(AUC 0.83,敏感度100%,特异度67%)及平均血管体粒子密度≥11.4×10³/ml(AUC 0.81,敏感度83%,特异度79%)预测完全病理坏死(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine comprehensive treatment parameters predictive of complete pathologic necrosis (CPN) in early-stage hepatocellular carcinoma (HCC) treated with glass microsphere radiation segmentectomy (RS). METHODS: This study is a secondary analysis of 61 tumors with available post-treatment imaging from a previously published cohort treated with RS using Yttrium-90-containing glass microspheres prior to liver transplantation. Post-treatment Bremsstrahlung SPECT-CT single-compartment, multi-compartment, and voxel-based dosimetry analyses were performed using dose confirmation software and compared between tumors that achieved CPN vs. non-CPN. RESULTS: Median specific activity (SA [1242 vs. 867 Bq, p = 0.018]), total angiosome dose (577 vs. 352 Gy, p = 0.005) tumor dose (1086 vs. 738 Gy, p = 0.007), and angiosome hepatic parenchymal dose (490 vs. 309 Gy, p = 0.005) were higher in the CPN (n = 43) vs. non-CPN (n = 18) cohort. Receiver operating characteristic (ROC) curve analyses (area under the curve [AUC], sensitivity, specificity) demonstrated that a SA ≥ 570 Bq (0.69, 88%, 50%), total angiosome dose ≥ 439 Gy (0.73, 70%, 67%), tumor dose ≥ 844 Gy (0.72, 76%, 67%), and angiosome hepatic parenchymal dose ≥ 420 Gy (0.73, 60%, 78%) were predictive of CPN (p < 0.05). No statistical difference was found between the tumor or angiosome particle density (PD), tumor volume, or angiosome volumes in the CPN and non-CPN cohorts. Subgroup ROC analysis of tumors that received SA < 570 Bq (n = 15) demonstrated that a total angiosome dose ≥ 263 Gy (0.85, 83%, 89%) and tumor dose ≥ 451 Gy (0.83, 100%, 67%) and were predictive of CPN (p < 0.05). An average angiosome PD ≥ 11.4 × 103/ml (AUC 0.81) was 83% sensitive and 79% specific to predict CPN in this subgroup (p < 0.05). 88% of tumors that were treated above all identified treatment parameter thresholds achieved CPN, compared to zero of those which did not meet a single criterion. Tumors fulfilling all single-compartment treatment parameter thresholds also met all multi-compartment dosimetry thresholds. CONCLUSION: CPN was predicted by a SA of ≥ 570 Bq, total angiosome dose of ≥ 439 Gy, tumor dose of ≥ 844 Gy, and angiosome hepatic parenchymal dose ≥ 420 Gy. A total angiosome PD of ≥ 11.4 × 103/ml was associated with CPN in tumors treated with SA < 570 Bq. Both single-compartment and multi-compartment dosimetry had similar performance when optimized per the identified thresholds. CLINICAL TRIAL REGISTRATION: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Montazeri SA, De la Garza-Ramos C, Silver C, et al. Achieving Complete Pathologic Necrosis in Hepatocellular Carcinoma Treated with Radiation Segmentectomy before Liver Transplantation: A Comprehensive Glass Microsphere Analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40064708. doi:10.1007/s00259-025-07179-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。